Standard Chemotherapy: Clinical Trials

44 trials of Standard Chemotherapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 6 recruiting, 6 unknown, 5 not yet recruiting. 22 Phase 2, 15 Phase 3, 4 Phase 4, 3 Not applicable, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 222Completed 9, Unknown 4, Not yet recruiting 3, Terminated 3, Active not recruiting 1, Recruiting 1, Withdrawn 1
Phase 315Completed 8, Recruiting 3, Active not recruiting 2, Unknown 2
Phase 44Not yet recruiting 2, Recruiting 1, Terminated 1
Not applicable3Completed 1, Recruiting 1, Terminated 1
Phase 13Active not recruiting 1, Not yet recruiting 1, Terminated 1

Follow Standard Chemotherapy: new trials by email Literature Review of Standard Chemotherapy trials Research Report on Standard Chemotherapy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Post-Marketing Trial to Evaluate the Safety and Efficacy of Quizartinib in Chinese Participants With Newly Diagnosed FMS-like Tyrosine Kinase 3-internal Tandem Duplication [FLT3-ITD] (+) Acute Myeloid Leukemia (AML)
Quizartinib, Chemotherapy, Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) - Acute Myeloid Leukemia
Phase 4Not yet recruitingDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company402026-12-012026-11-19
Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans
Toripalimab, Anlotinib, Standard Chemotherapy - Dermatofibrosarcoma Protuberans (DFSP)
Phase 2Not yet recruitingYanjie Zhang, MD202026-06-152026-06-16
Immune Cell Therapy for Advanced Solid Tumors
Autologous immune Cells, Standard chemotherapy - Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic)
Phase 1 / Phase 2Not yet recruitingLiaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.482025-12-012025-12-02
Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
TAS-102+bevacizumab+local treatment, Standard chemotherapy - Metastatic Colorectal Cancer (CRC)
Phase 2RecruitingFudan University1192025-02-282025-08-06
HVA vs IA/DA or VA in the Treatment of ND HR-AML
HVA, VA, Standard Chemotherapy - Newly Diagnosed Acute Myeloid Leukemia With High Risk
Phase 3RecruitingNanfang Hospital, Southern Medical University8762025-01-012025-02-06
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Quizartinib, Placebo, Chemotherapy - Leukemia
Phase 3Active not recruitingDaiichi Sankyo7002024-11-192026-07-02
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
Surufatinib, Serplulimab, standard chemotherapy - ESCC, Biliary Tract Cancer
Phase 2Not yet recruitingRenJi Hospital802024-08-102024-07-31
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
GEN1055, Pembrolizumab, Standard Chemotherapy - Malignant Solid Tumor
Phase 1 / Phase 2TerminatedGenmab212024-05-142026-08-11
The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
Huaier granule, chemotherapy drugs - Pancreatic Cancer Resectable
Phase 4RecruitingXi'an Jiaotong University6422024-05-062024-05-08
Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer
Huaier Granule, Capecitabine - Pancreatic Cancer Non-resectable
Phase 4Not yet recruitingXi'an Jiaotong University4882024-05-012024-04-29
A Global, Integrated, Personalized, Stage-related, Multimodal Therapeutic Approach for Rectal Adenocarcinoma Based on Organ Sparing and Mininvasivity
Sparing Approach, experimental chemoradiotherapy, Standard Chemotherapy - Rectal Adenocarcinoma, Non Metastatic
Not applicableRecruitingFondazione del Piemonte per l'Oncologia2002024-04-302026-03-05
A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer
Fuzaparib, standard chemotherapy - HR+/HER2- Early Breast Cancer
Phase 2CompletedXijing Hospital282023-03-032026-04-13
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Venetoclax, Placebo, Standard chemotherapy - Acute Myeloid Leukemia
Phase 3RecruitingUniversity of Ulm6502022-09-132026-11-12
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab - Mesothelioma, Pleural Mesothelioma
Phase 3CompletedPrECOG, LLC.2142021-02-182026-10-22
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
Azacitidine, Standard Chemotherapy, Allogeneic stem cell transplantation - High-risk MDS
Phase 3RecruitingGruppo Italiano Malattie EMatologiche dell'Adulto2742020-11-272025-04-29
Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer
UCPVax + Nivolumab, standard chemotherapy - Advanced Non-small Cell Lung Cancer
Phase 2CompletedCentre Hospitalier Universitaire de Besancon602020-09-092025-02-05
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study
Pressurized intraperitoneal aerosol chemotherapy (PIPAC), Standard chemotherapy - Gastric Adenocarcinoma, Cancer Metastatic
Phase 2CompletedAssistance Publique - Hôpitaux de Paris662020-06-112024-09-19
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
Abemaciclib, Fulvestrant, Standard Chemotherapy - Metastatic Breast Cancer
Phase 4TerminatedEli Lilly and Company42019-08-142021-08-24
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
ChemoID Assay, Standard Chemotherapy - Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Phase 3Active not recruitingCordgenics, LLC1502019-07-262024-08-22
Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy
Synchronous resection of primary pancreatic cancer and liver oligometastasis, Standard chemotherapy - Pancreatic Cancer, Liver Metastases
Phase 3UnknownFudan University3002018-07-012018-10-09

Showing 20 of 44. Sign in to see all of them.

Conditions studied

Breast Neoplasms (7)  ·  Leukemia, Myeloid, Acute (6)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Colonic Neoplasms (3)  ·  Colorectal Neoplasms (3)  ·  Neoplasm Metastasis (3)  ·  Ovarian Neoplasms (3)  ·  Pancreatic Neoplasms (3)  ·  Leukemia (2)  ·  Neoplasms (2)  ·  Rectal Neoplasms (2)  ·  Stomach Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Adenocarcinoma of Lung (1)  ·  Biliary Tract Neoplasms (1)

Sponsors

Hoffmann-La Roche (5)  ·  Amgen (2)  ·  Fudan University (2)  ·  University of Ulm (2)  ·  Xi'an Jiaotong University (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Centre Hospitalier Universitaire de Besancon (1)  ·  Cordgenics, LLC (1)  ·  Daiichi Sankyo (1)  ·  Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (1)  ·  Dana-Farber Cancer Institute (1)  ·  Eli Lilly and Company (1)  ·  Fondazione del Piemonte per l'Oncologia (1)  ·  Genentech, Inc. (1)  ·  Genmab (1)

Countries

United States (10)  ·  France (9)  ·  China (7)  ·  Germany (7)  ·  Spain (7)  ·  Italy (6)  ·  Australia (4)  ·  Belgium (4)  ·  Canada (4)  ·  Czechia (4)  ·  Austria (3)  ·  Netherlands (3)  ·  Norway (3)  ·  Poland (3)  ·  United Kingdom (3)

Top investigators

Hartmut Doehner, MD (2)  ·  Zheng Wang, PhD (2)  ·  Ajay K Kakkar, PhD (1)  ·  Anna Nowak, MD (1)  ·  Cary Presant, MD (1)  ·  David SP Tan (1)  ·  Felice Borghi, MD (1)  ·  Guopan Yu (1)  ·  Jalid Sehouli, Prof. Dr. med. (1)

Results publications

PMID 22377126, PMID 22924433, PMID 24638013, PMID 26342236, PMID 27993804, PMID 28738258, PMID 31818843, PMID 32179448, PMID 32591370, PMID 33358660, PMID 34499875, PMID 35709412, PMID 37187198, PMID 38428265, PMID 39546748, PMID 41146443, PMID 42434847

NIH funding

2023 (2), 2008 (1), 2018 (1)